KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Goodwill & Intangibles (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Goodwill & Intangibles for 6 consecutive years, with $41.2 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Goodwill & Intangibles changed N/A year-over-year to $41.2 million, compared with a TTM value of $41.2 million through Mar 2025, changed N/A, and an annual FY2024 reading of $89.9 million, up 88.09% over the prior year.
  • Goodwill & Intangibles was $41.2 million for Q1 2025 at AbCellera Biologics, down from $89.9 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $210.8 million in Q3 2022 and bottomed at $31.5 million in Q1 2021.
  • Average Goodwill & Intangibles over 5 years is $108.8 million, with a median of $89.9 million recorded in 2024.
  • The sharpest move saw Goodwill & Intangibles skyrocketed 223304.26% in 2021, then tumbled 73.34% in 2023.
  • Year by year, Goodwill & Intangibles stood at $196.2 million in 2021, then fell by 8.61% to $179.3 million in 2022, then crashed by 73.34% to $47.8 million in 2023, then soared by 88.09% to $89.9 million in 2024, then tumbled by 54.19% to $41.2 million in 2025.
  • Business Quant data shows Goodwill & Intangibles for ABCL at $41.2 million in Q1 2025, $89.9 million in Q4 2024, and $47.8 million in Q2 2024.